tbuckley/cabot-search huggingface dataset:
The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion
Authors: Jana Brezinova, Iveta Sarova, Halka Lhotska, Sarka Ransdorfova, Silvia Izakova, Karla Svobodova, Jana Markova, Zuzana Zemanova, Jaroslav Cermak, Anna T. Jonasova, Kyra Michalova
Journal: Blood (2014)
HIF-1a Expression and Implication in the Resistance Regulation and Malignancy in Pediatric Lymphomas Non-Hodgkin’s Tissue Arrays
Authors: Rosendo Luria-Pérez, Yolanda Rocio Peña-Alonso, Daniel Dimitri Hernández-Cueto, Altagracia Maldonado-Valenzuela, Guillermina Juliana Baay-Guzmán, Guadalupe Diaz-Elizondo, Luis Andrés Lara-Martínez, Glenda Juárez-Caballero, Mario I. Vega, Benjamin Bonavida, Sara Huerta-Yepez
Journal: Blood (2008)
Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis
Authors: Anuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, Amit Sharma, Haiyang Yun, Kerstin Görlich, Martin Wichmann, Adrian Schwarzer, Matthias Preller, Felicitas Thol, Johann Meyer, Reinhard Haemmerle, Eduard A. Struys, Erwin E. Jansen, Ute Modlich, Zhixiong Li, Laura M. Sly, Robert Geffers, Robert Lindner, Dietmar J. Manstein, Urlich Lehmann, Jürgen Krauter, Arnold Ganser, Michael Heuser
Journal: Blood (2012)
Diagnostic Value of Allergy Testing in Children Undergoing Four-Food Elimination Diet for Eosinophilic Esophagitis
Authors: Melanie M. Makhija, Joshua B. Wechsler, Carla M. Davis, Anthony P. Olive, Seth Marcus, Mirna Chehade, Barry K. Wershil, Amir F. Kagalwalla
Journal: Journal of Allergy and Clinical Immunology (2017)
Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway.
Authors: Jian-Jun Zhao, Jianhong Lin, Zhangbo Chu, Qi Wang, Kohichi Takada, Mala Mani, Bryan Ciccarelli, Teru Hideshima, Tai Yu-Tzu, Jianguo Tao, Steven P. Treon, Nikhil C. Munshi, Kenneth C. Anderson, Ruben Carrasco
Journal: Blood (2010)
Histone Demethylase Inhibition As a Novel Therapeutic Strategy in Myeloma
Authors: Charlotte Pawlyn, Edward Hookway, Peter Cain, Laurynas Pliuskys, Martin F Kaiser, Michael Bright, Lauren I Aronson, Alexander Murison, Morten Lindow, Susanna Obad, Henrik Oerum, Udo Opperman, Gareth J. Morgan, Faith E Davies
Journal: Blood (2014)
Sarcopenia to predict tolerance of adjuvant breast cancer chemotherapy.
Authors: Michael S. Sabel, Anna S.C. Conlon, Kent A. Griffith, Michael Englesbe, Stewart Wang
Journal: Journal of Clinical Oncology (2012)

138 Background: Despite improved survival with adjuvant chemotherapy among older women, it is less often recommended for fear they cannot complete therapy or will have excessive toxicity. Analytic morphometrics uses objective imaging measurements such as muscle size, bone mineral density (BMD) and body composition to improve risk stratification. We examined whether morphometrics might help predict toxicity of chemotherapy in breast cancer patients. Methods: Our prospective IRB-approved breast cancer database was queried for all patients who underwent adjuvant or neoadjuvant chemotherapy and had CT scans of the chest, abdomen and pelvis prior to chemo. Complications of chemotherapy were graded according to the NCI-CTC. CT scans were processed using semi-automated algorithms (MATLAB v13.0) to measure psoas area (PA) and density (PD), BMD and subcutaneous fat (SF), visceral fat (VF), and total body area (TBA. Outcome (DFS and OS) was assessed by K-M, and logistic regression models and ANOVA were used for toxicity events. Results: We identified 129 patients, ranging in age from 24 to 83 (median 52). 105 (81%) received AC/T while 19% received alternate regimens, all full weight based. T-stage, nodal status and HER2 expression were significantly associated with measures of obesity, except BMI, but not sarcopenia. After adjusting for stage and Her-2, BMI remained a significant predictor of DFS (OR 1.07 (95%CI 1.01, 1.13)) and OS (OR 1.06 (95% CI 1.00, 1.12)).After controlling for age, PD and VF were predictors of chemotherapy completion. The OR for completing chemotherapy decreased 0.95 (95% CI: 0.90, 1.01, p=0.08) for every increase of 1000 in VF and increased 1.08 (95% CI: 1.01, 1.15, p=0.03) for every unit increase in PD. Sarcopenia was associated with an increased risk of pulmonary complications (p=0.01) and anemia (p=0.06). Conclusions: Although age is a significant predictor of increased toxicity and inability to complete chemotherapy, sarcopenia is an objective, independent predictor of chemotherapy completion. Psoas density, easily obtainable from a pre-treatment CT scan, can help the clinician older breast cancer patients for adjuvant chemotherapy.
Truncation of BRAF and Raf1 in prostate cancer in China.
Authors: Yong-Jie Lu, Xiaoyan Liu, Xueying Mao, Lucy Hylands, Jeremy Clark, Colin Cooper, Guoping Ren
Journal: Journal of Clinical Oncology (2012)

77 Background: Chromosome translocations and fusion genes have been identified as common events in carcinomas in recent years and TMPRSS2:ERG fusions have been found in about half of human prostate cancers. However, by genome-wide analysis of Chinese prostate cancer cases, we found that certain genomic alterations, commonly identified in prostate cancer samples from the Western countries, occurred at a very low frequency in China, including the fusion of TMPRSS2:ERG. In 2010, recurrent fusion genes involving the RAF family gene BRAF and Raf1 were identified (Palanisamy et al, Nature Med. 16:793). Although the frequency of fusions involving BRAF and Raf1 are at a much lower frequency than fusion of TMPRSS2:ERG, BRAF and Raf1 are drugable, making them potential therapeutic targets. As the TMPRSS2:ERG fusion is infrequent in Chinese prostate cancers, we investigated if fusions involving BRAF and Raf1 occur at a higher frequency in prostate cancer in China than in Western countries. Methods: We used the fluorescence in situ hybridization signal split apart approach on prostate cancer samples made into tissue microarrays to detect the frequency of BRAF and Raf1 truncations. Three BAC probes on each side (5’ and 3’) of the two genes were labeled differentially using biotin and digoxigenin and subsequentially detected as red and green fluorescent signals, respectively. Results: We found that BRAF was truncated in four (two split signals, one 5’ deletions and one 3’ deletions) of the 193 informative cases (2.07%) and RAFaf1 (two 5’ deletions and one split signals) was truncated in three of 201 informative cases (1.49%). Although in some cases, three or four copies of these genes were detected, extensive copy number gain caused by amplification was not detected. Conclusions: These results indicate that truncations and potentially fusion of BRAF and Raf1 exist in Chinese prostate cancer, but at a similar low frequency as found in the Western samples (6/349 for BRAF and 4/450 for Raf1). Further studies are required to confirm the functional consequence of these truncations and to evaluate the therapeutic value of targeting these genes in this sub-group of prostate cancers.
Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial
Authors: W. R. Sukov, D. V. Miller, A. C. Dueck, K. S. Tenner, R. B. Jenkins, P. A. Kaufman, N. E. Davidson, S. R. Dakhil, S. Martino, V. Roy, E. A. Perez
Journal: Journal of Clinical Oncology (2009)

520 Background: Targeted therapy using trastuzumab (an anti-HER-2 receptor monoclonal antibody) has significantly improved survival in breast carcinoma patients (pts), but determining which pts will respond to this therapy remains a challenge. We previously reported (Miller DV, ASCO 2004 abstract #568) a subset of pts with breast cancers demonstrating focal HER-2 amplified clones (FHAC) amidst otherwise nonamplified tumor cells by fluorescence in-situ hybridization. These accounted for 21% of the HER-2 amplified but immunohistochemistry (IHC) negative cases and 30% of the HER-2 amplified but IHC equivocal cases. The clinical significance of this phenomenon was unclear at that time. We now report the disease-free survival (DFS) data on 91 FHAC pts with a comparison to the diffusely amplified (DA) cases in this trial group. Methods: Breast tumors were evaluated for HER-2 gene amplification using PathVysion™. FHAC cases demonstrated 2–40% of cells with &gt;10 HER-2 signals and HER-2:CEP17 ratio &gt;5.0, regardless of the overall HER-2:CEP17 ratio. Patient and disease characteristics were compared using chi-square tests. Cox regression models compared DFS between pts randomized to arms A (standard chemotherapy) and C (standard chemotherapy with concurrent trastuzumab) within 91 FHAC and 1571 DA cases. Median follow up was 4.0 years. Results: Age, race, menopausal status, surgical procedure, nodal status, histologic type and grade, and tumor size, were not significantly different between pateints with FHAC and DA. Pateints with FHAC had more frequent hormone receptor positivity compared to DA cases (66% vs 50%; p = 0.004). Hazard ratios between pts with FHAC and DA showed that both groups of pts had similar DFS (A: HR = 0.86, p = 0.65; C: HR = 0.72, p = 0.57). Hazard ratios between arms within FHAC and DA groups demonstrated similar benefit from trastuzumab in each group (FHAC: HR = 0.50, p = 0.30; DA: HR = 0.59, p &lt; 0.0001). Results remained consistent when including hormone receptor status in the model. Conclusions: Based on a small number (n = 91) of pts with FHAC, benefit from trastuzumab appears to be similar whether the population of HER-2 amplified cells with breast carcinomas is focal or diffuse. [Table: see text]
Febrile illness in healthcare workers caring for Ebola virus disease patients in a high-resource setting
Authors: Douglas Fink, Ian Cropley, Michael Jacobs, Stephen Mepham
Journal: Eurosurveillance (2017)

Ebola virus disease (EVD) patients treated in high-resource facilities are cared for by large numbers of healthcare staff. Monitoring these healthcare workers (HCWs) for any illness that may represent transmission of Ebola virus is important both for the individuals and to minimise the community risk. International policies for monitoring HCWs vary considerably and their effectiveness is unknown. Here we describe the United Kingdom (UK) experience of illness in HCWs who cared for three patients who acquired EVD in West Africa. Five of these 93 high-level isolation unit (HLIU) HCWs presented with fever within 21 days of working on the unit; one of these five presented outside of the UK. This article discusses different approaches to monitoring of HCW symptom reporting. The potential impact of these approaches on HLIU staff recruitment, including travel restrictions, is also considered. An international surveillance system enhancing collaboration between national public health authorities may assist HLIU HCW monitoring in case they travel.
OS7.7 Feasibility and toxicity of concomitant radiochemotherapy with vincristine in adult patients with medulloblastoma - results from the NOA-07 trial
Authors: C. Seidel, C. Reimers, D. Beier, T. Pietsch, M. Warmuth-Metz, U. Bogdahn, R. Kortmann, P. Hau
Journal: Neuro-Oncology (2016)
Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia
Authors: Lili Tao, Qingshu Zeng, June Li, Miao Xu, Jiajia Wang, Ying Pan, Huiping Wang, Qianshan Tao, Yang Chen, Jun Peng, Ming Hou, Arend Jan Gerard Jansen, Heyu Ni, Zhimin Zhai
Journal: Journal of Hematology & Oncology (2017)

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder. Despite considerable investigation, the pathogenesis of ITP remains incompletely understood, and for many patients, effective therapy is still unavailable. Using murine models and in vitro studies of human blood samples, we recently identified a novel Fc-independent platelet clearance pathway, whereby antibody-mediated desialylated platelets can be cleared in the liver via asialoglycoprotein receptors, leading to decreased response to standard first-line therapies targeting Fc-dependent platelet clearance. Here, we evaluated the significance of this finding in 61 ITP patients through correlation of levels of platelet desialylation with the efficacy of first-line therapies. We found that desialylation levels between different responses to treatment groups were statistically significant (p < 0.01). Importantly, correlation analysis indicated response to treatment and platelet desialylation were related (p < 0.01), whereby non-responders had significantly higher levels of platelet desialylation. Interestingly, we also found secondary ITP and certain non-ITP thrombocytopenias also exhibited significant platelet desialylation compared to healthy controls. These findings designate platelet desialylation as an important biomarker in determining response to standard treatment for ITP. Furthermore, we show for the first time platelet desialylation in other non-ITP thrombocytopenias, which may have important clinical implications and deserve further investigation.
The impact of physician use of electronic medical records on colorectal cancer screening.
Authors: Devon Paula Richardson, Corinne Daly, Qing Li, Rinku Sutradhar, Elisabeth M. Del Giudice, Lawrence Frank Paszat, Jill Tinmouth, Linda Rabeneck, Nancy N. Baxter
Journal: Journal of Clinical Oncology (2014)

288 Background: The use of electronic medical records (EMR) by primary care physicians (PCP) is promoted as a method to enhance screening rates, however the impact of these systems on screening participation is uncertain. The purpose of this study was to determine if the use of EMR among a population-based sample of Ontario PCPs affects the colorectal cancer (CRC) screening participation of their patients. Methods: A survey was sent to 1,463 randomly selected PCPs in Ontario regarding adoption of EMR and cancer screening management enabled by EMR. Patients who were treated by PCP survey respondents were identified from administrative health care databases and were included if they were eligible for CRC screening (age 50-74) during the study window (April 1, 2012 – March 31, 2013). We identified patients who were up to date with CRC screening (FOBT within 2 years, flexible sigmoidoscopy within 5 years or colonoscopy within 10 years) as of March 31, 2013. Logistic regression models were created to examine the association between EMR usage and screening participation, adjusted for physician practice model, physician sex, years in practice, patient age patient sex, patient SES, and patient comorbidities using propensity scores. Results: A total of 855 PCPs responded to the survey (58.4% response rate) and 845 could be linked to administrative databases. The patient cohort included 330,441 eligible patients linked to a PCP included in the study. The proportion of patients up to date with CRC screening as of March 31, 2013 was 61.6% (203,720/330,441). After propensity score adjustment, patients were more likely to be up to date with CRC screening if their physician used an EMR (OR 1.16, 95% CI 1.04 – 1.29). Conclusions: PCP use of EMR was associated with a small, but measurable increase the likelihood that their patients were up to date with CRC screening. Enhanced use of the EMR might improve the uptake of CRC screening on a population level.
An In Vitro and In Vivo Evidence That Downregulation of Leukemia Inhibitory Factor (LIF) Receptor (LIF-R) Decreases the Metastatic Potential of Human Rhabdomyosarcoma (RMS) Cells.
Authors: Marcin Wysoczynski, Katarzyna Miekus, Anna Marcinkowska, Anna Janowska-Wieczorek, Mariusz Z. Ratajczak
Journal: Blood (2006)
Overall Survival (OS) of Acute Lymphoblastic Leukemia (ALL) Is Better When Initial Therapy Is Administered in Academic Hospitals (AH) Versus Non-Academic Hospitals (NAH): A Retrospective Analysis of the National Cancer Data Base (NCDB)
Authors: Roberto A. Ferro, Valerie Shostrom, Julie M. Vose, Krishna Gundabolu, Smith Giri, KM Monirul Islam, Lori J. Maness, James Olen Armitage, Vijaya R. Bhatt
Journal: Blood (2015)
Examining potential cancer care disparities in an equal access system: Quality of colorectal cancer care (CRC) in the Veterans Affairs (VA) health care system.
Authors: Leah L. Zullig, William Ruffin Carpenter, David H. Abbott, Dawn T. Provenzale, Morris Weinberger, Bryce B. Reeve, George L. Jackson
Journal: Journal of Clinical Oncology (2012)

229 Background: Racial disparities in cancer treatment and outcomes are a substantial problem nationally. The Veterans Affairs (VA) health system is nationwide, with goals of being equal access and delivering high-quality care; however, the presence or extent of racial disparities in CRC treatment and outcomes within the VA is poorly understood. We examined the relationship between race and receipt of National Comprehensive Cancer Network guideline-concordant CRC care in the VA. Methods: We identified 2,896 patients diagnosed with incident CRC between October 1, 2003 and March 31, 2006 from 128 VAMCs. We included white and black patients with invasive, non-metastatic disease, known comorbidity status, age, and marital status. Multivariable logistic regression examined the association between race and receipt of guideline-concordant care (CT scan, preoperative CEA, clear surgical margins, referral to medical oncology for stages II to III; receipt of 5FU-based adjuvant chemotherapy for stage III; receipt of surveillance colonoscopy for stages I-III). Explanatory variables included demographic and disease characteristics. Results: In the final sample of 2,022 men, mean age at diagnosis was 68 years; 85% were white, 52%, married, and 38% lived in the South. Stage was evenly distributed. No significant racial differences existed for most guidelines. Compared to blacks, whites were more likely to undergo surveillance colonoscopy 6 to 18 months following surgery (OR=1.32, 95% CI 1.01-1.73, p=0.04) and marginally more likely to be referred to medical oncology (OR=1.46, 95% CI 1.00-2.13, p=0.05). Patients who were 75 years or older at diagnosis (p&lt;0.01) or with cardiovascular-related comorbidities (OR=0.65, 95% CI 0.50-0.89, p=0.01) were less likely to be referred to a medical oncologist than their younger, healthier counterparts. Conclusions: In general, the VA provides high quality, equal access cancer care; however, there may be room for improvement.
PII trial of zoledronic acid in NSCLC pts with bone metastases and elevated marker of osteoclast activity
Authors: Minoru Fukuda, Takeshi Kitazaki, Taishi Harada, Takayuki Suetsugu, Masayuki Kawasaki, Hiroshi Wataya, Makoto Furugen, Shoji Tokunaga, Koichi Takayama, Kenji Sugio
Journal: Annals of Oncology (2016)
FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma.
Authors: Hidenobu Takahashi, Friedrich Feuerhake, Jeffery L. Kutok, Stefano Monti, Paola S. Dal Cin, Donna Neuberg, Jon C. Aster, Margaret A. Shipp
Journal: Blood (2005)
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study
Authors: Ajay K. Gopal, Stephen J. Schuster, Nathan Fowler, Judith Trotman, Georg Hess, Jing-Zhou Hou, Abdulraheem Yacoub, Michael Lill, Peter Martin, Umberto Vitolo, Wojciech Jurczak, James Morton, Dzhelil Osmanov, Gary J. Gartenberg, Jessica Vermeulen, Sriram Balasubramanian, Shean-sheng Wang, Sanjay Deshpande, Gilles A. Salles
Journal: Blood (2016)
Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer
Authors: Chuan He, Libo Wang, Jiantao Zhang, Hong Xu
Journal: Molecular Cancer (2017)

Hypoxia plays an important role in the development of various cancers. MicroRNAs (miRNAs) act as post-transcriptional regulators of gene expression and modulate the tumorigenesis, including gastric cancer. However, the roles and molecular mechanism of miR-224 in gastric cancer under hypoxia remain poorly understood. Real-time PCR and Northern blot assay were used to examine the effects of hypoxia and HIF-1α on miR-224 expression. Luciferase and ChIP assays were performed to determine whether miR-224 was a transcriptional target of HIF-1α. Then MTT, colony formation, in vitro scratch and invasion assays were used to detect the effects of miR-224 on cell growth, migration and invasion under hypoxia, as well as the in vivo animal study. Luciferase assay and Western blot were performed to validate the targets of miR-224. Functional studies were performed to determine the roles of RASSF8 as that of miR-224 under hypoxia. The effects of RASSF8 knockdown on the transcriptional activity and translocation of NF-κB were investigated using Luciferase assay and Western blot, respectively. Finally, the expression levels of miR-224 and RASSF8 were detected using real-time PCR in gastric cancer tissues as well as lymph node metastasis tissues. We demonstrated that miR-224 was upregulated by hypoxia and HIF-1α. HIF-1α affected miR-224 expression at the transcriptional level. MiR-224 inhibition suppressed cell growth, migration and invasion induced by hypoxia, while miR-224 overexpression resulted in opposite effects. MiR-224 inhibition also suppressed tumor growth in vivo. We then validated that RASSF8 was a direct target of miR-224. RASSF8 overexpression inhibited cell growth and invasion, while RASSF8 knockdown ameliorated the inhibitory effects of miR-224 inhibition on cell growth and invasion. Furthermore, we found that RASSF8 knockdown enhanced the transcriptional activity of NF-κB and p65 translocation, while RASSF8 overexpression resulted in opposite effects. Inhibition of NF-κB activity by PDTC attenuated the effects of RASSF8 knockdown on cell proliferation and invasion. Finally, miR-224 was upregulated in both gastric cancer tissues and lymph node metastasis positive tissues, while RASSF8 expression was opposite to that of miR-224. These results indicate that hypoxia-inducible miR-224 promotes gastric cancer cell growth, migration and invasion by downregulating RASSF8 and acts as an oncogene, implying that inhibition of miR-224 may have potential as a therapeutic target for patients with hypoxic gastric tumors.
Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).
Authors: Gloria N. Mattiuzzi, Gladys Alvarado, Hagop M. Kantarjian, Srdan Verstovsek, Maria Cabanillas, Stefan Faderl, Joann T. Lim, Francis Giles, Miloslav Beran, Susan O’Brien, Elihu H. Estey
Journal: Blood (2004)
Anti-Tumor Effect of INNO-406, a Novel Bcr-Abl Inhibitor in Combination with Cyclosporin A Against the Murine Central Nervous System and Systemic Leukemia Model.
Authors: Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa
Journal: Blood (2007)
PD-L1 expression and tumor immune-cell infiltration in non-small cell lung cancer from HIV-infected patients
Authors: M. Wislez, C. Domblides, M. Antoine, C. Hamard, N. Rabbe, A. Rodenas, T. Vieira, P. Créquit, J. Cadranel, A. Lavolé
Journal: Annals of Oncology (2016)
Timing of Mesenchymal Stem Cell Co-Transplantation and Site of Bone Engraftment Determine Levels of Hematopoietic Engraftment and Contribution of HSC to the Bone Niche
Authors: Evan Colletti, Saloomeh Mokhtari, Chad Sanada, Esmail D Zanjani, Christopher D Porada, Graca Almeida-Porada
Journal: Blood (2010)
BMS-214662 Eliminates Quiescent and Proliferating Acute Myeloid Leukemia Cells through Activation of Protein Kinase Cβ and Enhances the Efficacy of Cytosine Arabinoside
Authors: Francesca Pellicano, Amy Sinclair, Alan Hair, Tessa L. Holyoake, Mhairi Copland
Journal: Blood (2010)
Impact of Hospital-Wide Guideline for Antimicrobial Stewardship in Patients with History of Beta-Lactam Allergy at an Academic Medical Center
Authors: Shayna Ravindran, Michael Beshir, Sheila Wang, Sindhura Bandi, Amy Hanson, Tristan O'Driscoll, Mary C. Tobin
Journal: Journal of Allergy and Clinical Immunology (2017)